Financial Performance - The company's operating revenue for Q1 2025 was ¥81,300,127.46, a decrease of 27.01% compared to ¥111,390,688.04 in the same period last year[4] - Net profit attributable to shareholders was ¥14,542,813.84, down 62.12% from ¥38,392,507.40 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥11,131,421.96, reflecting a decline of 68.00% compared to ¥34,787,360.92 in the previous year[4] - Basic and diluted earnings per share were both ¥0.04, a decrease of 60.00% from ¥0.10 in the same period last year[4] - Total operating revenue for Q1 2025 was ¥81,300,127.46, a decrease of 27% compared to ¥111,390,688.04 in Q1 2024[18] - Net profit for Q1 2025 was ¥14,542,813.84, a decline of 62% from ¥38,392,507.40 in Q1 2024[19] - Earnings per share for Q1 2025 was ¥0.04, compared to ¥0.10 in Q1 2024, indicating a 60% decrease[19] - Cash received from sales of goods and services in Q1 2025 was ¥90,331,179.04, down 30% from ¥129,981,796.53 in Q1 2024[21] Cash Flow and Assets - The net cash flow from operating activities decreased by 59.74%, amounting to ¥15,204,001.57, down from ¥37,767,684.23[4] - Total assets at the end of the reporting period were ¥1,815,591,513.49, a decrease of 0.90% from ¥1,832,158,296.89 at the end of the previous year[5] - As of March 31, 2025, the company's total current assets amounted to RMB 1,049,855,808.49, a decrease from RMB 1,067,681,904.23 as of December 31, 2024, reflecting a decline of approximately 1.14%[13] - The company's cash and cash equivalents stood at RMB 401,225,526.99, slightly increasing from RMB 400,252,111.81 in the previous period[13] - Total cash inflow from investment activities was $464,799,073.09, down from $503,609,819.16, resulting in a net cash outflow of $51,537,903.44 compared to a net inflow of $60,935,030.35 previously[22] - The ending balance of cash and cash equivalents was $106,768,979.00, significantly lower than $277,035,240.30 at the end of the previous period[23] Liabilities and Equity - Total liabilities decreased to ¥384,741,562.28 from ¥415,851,159.52, representing a reduction of approximately 7.5%[15] - Non-current liabilities totaled ¥237,393,000.93, a slight increase from ¥232,502,428.90[15] - The company reported a decrease in accounts payable from ¥66,627,322.85 to ¥36,201,224.37, a reduction of about 46%[15] - Shareholders' equity attributable to shareholders was ¥1,430,849,951.21, an increase of 1.03% from ¥1,416,307,137.37 at the end of the previous year[5] Research and Development - Research and development expenses totaled ¥17,156,877.91, a decrease of 14.62% from ¥20,095,592.77 year-on-year[4] - The proportion of R&D expenses to operating revenue increased to 21.10%, up 3.06 percentage points from 18.04%[5] - The company is focusing on R&D investments to enhance technology and product innovation, aiming to meet unmet clinical needs and drive import substitution[12] - The company has established a dual-driven strategy focusing on import substitution and clinical interactive innovation to enhance its product pipeline[12] - The company has a robust product pipeline prepared in advance to navigate industry challenges and aims to create a "new quality productivity" for long-term growth[12] Non-Recurring Gains and Other Income - The company reported non-recurring gains totaling ¥3,411,391.88, primarily due to various non-operating income sources[7] Shareholder Information - The top ten shareholders include Ningbo Baoshui District Yingweili Enterprise Management Partnership with 108,000,008 shares, representing a significant stake in the company[11]

4月28日，科美诊断今日收盘6.93元，下跌1.56%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到21.89倍，总市值27.80亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.40倍，行业中值34.81倍，科美诊断排 名第51位。 截至2025年一季报，共有9家机构持仓科美诊断，其中其他9家，合计持股数20628.76万股，持股市值 15.37亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)51科美诊断21.8921.871.9427.80亿行业平均 46.4044.004.49100.23亿行业中值34.8134.782.2645.22亿1硕世生物-1850.69-1850.691.1437.05亿2天益医 疗-1581.08-2708.221.6920.15亿3澳华内镜-525.57263.604.2155.39亿4诺唯赞-508.22-508.222.3391.96亿5康 泰医学-256. ...

4月16日，科美诊断今日收盘6.85元，下跌1.58%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到21.64倍，总市值27.48亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.94倍，行业中值29.64倍，科美诊断排 名第50位。 来源：金融界 科美诊断技术股份有限公司从事临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售，公司产品 为基于光激化学发光法的LiCA系列诊断试剂和基于酶促化学发光法的CC系列诊断试剂及仪器。是国内 最早专业从事临床免疫诊断中化学发光产品开发的专业化高科技企业之一。科美诊断荣获2022年北京市 知识产权示范单位、2022年度第二批北京市市级企业技术中心等荣誉称号。 最新一期业绩显示，2024年三季报，公司实现营业收入3.44亿元，同比-0.43%；净利润1.12亿元，同 比-6.73%，销售毛利率76.35%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)50科美诊断21.6421.641.9627.48亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56- ...

科美诊断2月28日大宗交易平台出现一笔成交，成交量60.00万股，成交金额459.60万元，大宗交易成交 价为7.66元，相对今日收盘价折价1.16%。该笔交易的买方营业部为机构专用，卖方营业部为中信证券 股份有限公司北京紫竹院路证券营业部。 两融数据显示，该股最新融资余额为1.78亿元，近5日增加3421.30万元，增幅为23.86%。（数据宝） 进一步统计，近3个月内该股累计发生17笔大宗交易，合计成交金额为6518.95万元。 2月28日科美诊断大宗交易一览 证券时报•数据宝统计显示，科美诊断今日收盘价为7.75元，下跌3.61%，日换手率为2.46%，成交额为 7778.51万元，全天主力资金净流出544.66万元，近5日该股累计下跌7.96%，近5日资金合计净流出 4187.62万元。 ...

Financial Performance - Total revenue for 2024 was RMB 43,628.98 million, a decrease of 2.03% compared to the previous year[5] - Operating profit for 2024 was RMB 13,475.09 million, down 18.96% year-over-year[5] - Net profit attributable to shareholders was RMB 12,699.28 million, reflecting a decline of 13.83% from the prior year[5] - Basic earnings per share decreased to RMB 0.32, a drop of 13.51% compared to the previous year[5] - The weighted average return on equity decreased to 9.17%, down 1.56 percentage points from the previous year[3] Assets and Operations - Total assets at the end of the reporting period were RMB 183,216.71 million, an increase of 0.64% from the beginning of the year[5] - The company launched the fully automated immunoassay system LICA® AT 5000, which gained recognition from high-end hospital clients[6] - The company’s R&D and production base in Suzhou has commenced operations, enhancing long-term growth potential[6] Strategic Focus - The company is focusing on precision medicine for diseases such as thyroid, reproductive assistance, cardiovascular, and central nervous system disorders[6] - The company is committed to a "dual-drive" strategy leveraging its leading LICA® technology platform for strong import substitution[6]

科美诊断2月17日大宗交易平台出现一笔成交，成交量50.00万股，成交金额411.50万元，大宗交易成交 价为8.23元，相对当日收盘价折价1.56%。该笔交易的买方营业部为中信证券股份有限公司总部(非营业 场所)，卖方营业部为中信证券股份有限公司北京紫竹院路证券营业部。（数据宝） 超级复盘、主力资金 大宗交易、大宗成交、折溢价、折价、溢价 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 主力资金 2月17日科美诊断大宗交易一览 ...

证券代码：688468 证券简称：科美诊断 公告编号：2024-068 科美诊断技术股份有限公司关于持股 5%以上股东 减持计划完成暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，科美诊断技术股份有限公司（以下简称"公司"）股东 上海沛禧投资管理合伙企业（有限合伙）（以下简称"上海沛禧"）及其一致行动 人 HJ CAPITAL 2 LIMITED（以下简称"HJ CAPITAL"）分别持有公司股份 17,708,910 股、11,273,384 股（合计持有 28,982,294 股），分别占公司总股本 4.41%、 2.81%（合计占公司总股本的 7.23%）。 上述股份来源均为公司首次公开发行股票并上市前持有的股份，且已于 2022 年 4 月 11 日解除限售并上市流通。 减持计划的实施结果情况 公司于 2024 年 10 月 14 日披露了《科美诊断技术股份有限公司关于持股 5% 以上股东减持股份计划公告》（公告编号：2024-0 ...

Group 1 - The core transaction on December 18 involved a block trade of 500,000 shares of Kemei Diagnostics, with a transaction value of 3.585 million yuan, at a price of 7.17 yuan, representing a discount of 0.69% compared to the closing price [1] - In the last three months, Kemei Diagnostics has recorded a total of 22 block trades, with a cumulative transaction value of 80.7089 million yuan [2] - The stock closed at 7.22 yuan on the same day, showing a slight increase of 0.14%, with a daily turnover rate of 1.37% and a total trading volume of 39.7594 million yuan [2] Group 2 - The net inflow of main funds for Kemei Diagnostics was 1.2076 million yuan, while the stock has seen a cumulative decline of 5.62% over the past five days, with a total net outflow of 2.1356 million yuan [2] - The latest margin financing balance for Kemei Diagnostics is 129 million yuan, which has increased by 11.8049 million yuan, reflecting a growth rate of 10.10% over the past five days [3]

证券代码：688468 证券简称：科美诊断 公告编号：2024-067 科美诊断技术股份有限公司关于持股 5%以上股东 减持计划完成暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 上述减持主体存在一致行动人： | | 股东名称 | 持股数量 | 持股比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | --- | | | | （股） | | | | 第一组 | 横琴君联致 康、LOYAL CLASS | 24,110,103 | 6.01% | 横琴君联致康的执行事务合伙 | | | | | | 人拉萨君祺企业管理有限公司 | | | | | | 系君联资本管理股份有限公司 | | | | | | 100%持股的企业，君联资本管 | | | | | | 理股份有限公司间接持有 | | | | | | LOYAL CLASS 40.29%的股权 | | | | | | 且为 LOYAL CLASS 的最终实 | | | | | | 际管理人。 | | | 合计 | ...

科美诊断技术股份有限公司 简式权益变动报告书 住所：上海市崇明区长兴镇潘园公路1800号2号楼8383室（上海泰和经济发 展区） 通讯地址：上海市崇明区长兴镇潘园公路 1800 号 2 号楼 8383 室（上海泰和 经济发展区） 信息披露义务人的一致行动人：HJ CAPITAL 2 LIMITED 住所：Room D, 3/F., Thomson Commercial Building, 8-10 Thomson Road, Wanchai, Hong Kong 通讯地址：Room D, 3/F., Thomson Commercial Building, 8-10 Thomson Road, Wanchai, Hong Kong 权益变动性质：股份减持 上市公司名称：科美诊断技术股份有限公司 股票上市地点：上海证券交易所 股票简称：科美诊断 股票代码：688468 信息披露义务人：上海沛禧投资管理合伙企业（有限合伙） 签署日期：2024年11月29日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公 司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 ...